NEW YORK and AMSTERDAM, Dec. 23, 2025 — Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “the Company”), a clinical-stage biopharmaceutical firm dedicated to improving patient outcomes through the development of effective, rapid-acting, and convenient mental health treatments, today announced that its common stock has been included in the NASDAQ Biotechnology Index (Nasdaq: NBI), effective before market open on Monday, December 22, 2025.
“2025 has proven to be a pivotal year for AtaiBeckley, marked by significant advancements across our pipeline and corporate structure. We strengthened our financial position by raising approximately $300 million, progressed multiple clinical programs towards late-stage development, solidified our leadership in next-generation mental health therapeutics through the strategic merger of atai Life Sciences and Beckley Psytech, and anticipate our corporate domiciliation to the U.S. around year-end,” stated Srinivas Rao, Chief Executive Officer of AtaiBeckley. “Looking ahead, AtaiBeckley is entering a crucial phase and is well-positioned to translate scientific leadership into long-term value for both patients and shareholders, a prospect further validated by our recent inclusion in the NBI.”
The NBI is designed to monitor the performance of a selection of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are categorized as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NBI is calculated using a modified capitalization-weighted methodology. Companies included in the NBI must fulfill specific eligibility criteria, such as minimum market capitalization, average daily trading volume, and a certain period as a public company, among other requirements. Nasdaq selects its constituents once annually in December.
The NBI is widely utilized by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. For additional details about the NBI, please visit .
About Atai Beckley N.V.
AtaiBeckley is a clinical-stage biopharmaceutical company committed to transforming patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. It was formed in November 2025 through the strategic combination of ATAI Life Sciences N.V. and Beckley Psytech Limited. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, all of which are currently in Phase 2 clinical development. The company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create new possibilities in mental health by offering effective, commercially scalable, and convenient interventional psychiatry therapies that can be seamlessly integrated into healthcare systems.
For the latest updates and to learn more about the AtaiBeckley mission, visit or follow the Company on and on .
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, as amended. We intend for such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements found in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are used to identify forward-looking statements, though not all forward-looking statements include these terms. Forward-looking statements encompass explicit or implied statements concerning, among other things: the potential benefits of the strategic combination; our business strategy and plans; the timing and potential advantages of the redomiciliation; statements regarding our inclusion in the Nasdaq Biotechnology Index; the potential, success, and timing of development and trial progress and related milestones for our product candidates; and management’s plans and objectives for future operations, research and development, and capital expenditures.
Forward-looking statements are neither promises nor guarantees but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected. These include, without limitation, the significant factors detailed in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as these factors may be updated periodically in AtaiBeckley’s other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, except as required by applicable law.
Contact Information
Investor Contact:
Media Contact:
